Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Opens in a new tab or window For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban.

New data from a clinical trial suggest that apixaban, an anticoagulant that’s widely been prescribed to promote recovery in patients with severe cases of COVID-19, doesn’t offer any discernable ...

Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open ...

Apixaban is an anticoagulant, which is used for reducing the risk of strokes and blood clots in patients with atrial fibrillation who have no problems with their heart valve (nonvalvular atrial ...

Further trials comparing aspirin with newer anticoagulants (dabigatran, apixaban and rivaroxaban) are necessary to assess the role of each agent in stroke prevention in patients with AF.

For people with HIV and atrial fibrillation (Afib or AF), certain oral anticoagulants (OACs) may carry a higher bleeding risk ...